

Tuberous Sclerosis Complex Market Expected to Experience Major Growth by 2034, According to DelveInsight

DelveInsight's Tuberous Sclerosis Complex Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES,
July 8, 2024 /EINPresswire.com/ --

DelveInsight's "Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Tuberous Sclerosis Complex, historical and

forecasted epidemiology as well as the Tuberous Sclerosis Complex market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



To Know in detail about the Tuberous Sclerosis Complex market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Tuberous Sclerosis Complex Market Forecast](#)

Some of the key facts of the Tuberous Sclerosis Complex Market Report:

The Tuberous Sclerosis Complex market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

According to Togi et al. (2022), Tuberous Sclerosis Complex (TSC) occurs in an estimated frequency of approximately one in 6000 to 10,000 individuals in the Japanese population. Among these cases, around two-thirds are sporadic, occurring randomly, while the remaining cases are found within families where there is a genetic predisposition to the condition.

According to the National Organization for Rare Disorders (NORD), Tuberous Sclerosis Complex (TSC) is a rare genetic disorder affecting 1 in 6,000 newborns in the United States. It is estimated that between 40,000 to 80,000 people in the United States have TSC. In Europe, the prevalence is estimated to range from approximately 1 in 25,000 to 1 in 11,300 individuals.

According to Orphanet, a database specializing in rare diseases and orphan drugs, the prevalence of Tuberous Sclerosis Complex (TSC) in the UK is estimated to be around 1 in 20,000 to 25,000 individuals.

Key Tuberous Sclerosis Complex Companies: Nobelpharma, Marinus Pharmaceuticals, Noema Pharma, Novartis, Jazz Pharmaceuticals, GRIN Therapeutics, Inc, Longboard Pharmaceuticals, Aadi Bioscience, Inc., and others

Key Tuberous Sclerosis Complex Therapies: NPC-12Y gel, Ganaxolone, Basimglurant (NOE-101), everolimus, Cannabidiol Oral Solution, Radiprodil, LP352, bexicaserin, nab-sirolimus, and others

The Tuberous Sclerosis Complex market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tuberous Sclerosis Complex pipeline products will significantly revolutionize the Tuberous Sclerosis Complex market dynamics.

Tuberous Sclerosis Complex Overview

Tuberous Sclerosis Complex (TSC) is a rare genetic disorder characterized by the growth of benign tumors in multiple organs of the body. These tumors can develop in various organs, including the brain, skin, kidneys, heart, eyes, lungs, and other organs.

Get a Free sample for the Tuberous Sclerosis Complex Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Tuberous Sclerosis Complex Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Tuberous Sclerosis Complex Epidemiology Segmentation:

The Tuberous Sclerosis Complex market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Tuberous Sclerosis Complex

Prevalent Cases of Tuberous Sclerosis Complex by severity

Gender-specific Prevalence of Tuberous Sclerosis Complex

Diagnosed Cases of Episodic and Chronic Tuberous Sclerosis Complex

Download the report to understand which factors are driving Tuberous Sclerosis Complex epidemiology trends @ [Tuberous Sclerosis Complex Epidemiology Forecast](#)

Tuberous Sclerosis Complex Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tuberous Sclerosis Complex market or expected to get launched during the study period. The analysis covers Tuberous Sclerosis Complex market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tuberous Sclerosis Complex Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Tuberous Sclerosis Complex Therapies and Key Companies

NPC-12Y gel: Nobelpharma

Ganaxolone: Marinus Pharmaceuticals

Basimglurant (NOE-101): Noema Pharma

everolimus: Novartis

Cannabidiol Oral Solution: Jazz Pharmaceuticals

Radiprodil: GRIN Therapeutics, Inc.

LP352, bexicaserin: Longboard Pharmaceuticals

nab-sirolimus: Aadi Bioscience, Inc.

Scope of the Tuberous Sclerosis Complex Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Tuberous Sclerosis Complex Companies: Nobelpharma, Marinus Pharmaceuticals, Noema Pharma, Novartis, Jazz Pharmaceuticals, GRIN Therapeutics, Inc, Longboard Pharmaceuticals, Aadi Bioscience, Inc., and others

Key Tuberous Sclerosis Complex Therapies: NPC-12Y gel, Ganaxolone, Basimglurant (NOE-101), everolimus, Cannabidiol Oral Solution, Radiprodil, LP352, bexicaserin, nab-sirolimus, and others

Tuberous Sclerosis Complex Therapeutic Assessment: Tuberous Sclerosis Complex current marketed and Tuberous Sclerosis Complex emerging therapies

Tuberous Sclerosis Complex Market Dynamics: Tuberous Sclerosis Complex market drivers and Tuberous Sclerosis Complex market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Tuberous Sclerosis Complex Unmet Needs, KOL's views, Analyst's views, Tuberous Sclerosis Complex Market Access and Reimbursement

To know more about Tuberous Sclerosis Complex companies working in the treatment market, visit @ [Tuberous Sclerosis Complex Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Tuberous Sclerosis Complex Market Report Introduction
2. Executive Summary for Tuberous Sclerosis Complex

3. SWOT analysis of Tuberous Sclerosis Complex
4. Tuberous Sclerosis Complex Patient Share (%) Overview at a Glance
5. Tuberous Sclerosis Complex Market Overview at a Glance
6. Tuberous Sclerosis Complex Disease Background and Overview
7. Tuberous Sclerosis Complex Epidemiology and Patient Population
8. Country-Specific Patient Population of Tuberous Sclerosis Complex
9. Tuberous Sclerosis Complex Current Treatment and Medical Practices
10. Tuberous Sclerosis Complex Unmet Needs
11. Tuberous Sclerosis Complex Emerging Therapies
12. Tuberous Sclerosis Complex Market Outlook
13. Country-Wise Tuberous Sclerosis Complex Market Analysis (2020–2034)
14. Tuberous Sclerosis Complex Market Access and Reimbursement of Therapies
15. Tuberous Sclerosis Complex Market Drivers
16. Tuberous Sclerosis Complex Market Barriers
17. Tuberous Sclerosis Complex Appendix
18. Tuberous Sclerosis Complex Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/726019429>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.